Patterns and Clinical Predictors of Antiseizure Medication Use in Pediatric Traumatic Brain Injury
Authors:
Preprint
- 26 August 2026
- preprint
- Published by Springer Nature in Research Square
Abstract
Objective Current guidelines recommend the use of antiseizure medications (ASM) in pediatric patients with severe traumatic brain injury (TBI). This is based on low-quality evidence and can lead to variability in practice and over-prescription of medications. To understand factors influencing ASM prescription in pediatric TBI, we examined clinical variables associated with inpatient and discharge ASM prescription. Methods Multi-center, retrospective cohort study of patients aged 0 to 21 years, admitted with TBI to the intensive care units at two Level I trauma centers, from 2016 through 2024. Obtained demographic and clinical information from chart review. Neuroimaging and electroencephalogram findings were extracted from reports. Primary outcome measure was ASM administration during inpatient hospitalization. Secondary outcome measure was prescription of ASMs at discharge. We developed multivariable logistic regression models to identify factors associated with inpatient and discharge ASM prescription, and report adjusted odds ratios (OR) with 95% confidence intervals (CI). Results 467 patients met inclusion criteria. 287 (61%) patients were given an ASM during their hospitalization, and 159 (34%) patients were discharged from the hospital on an ASM. Factors associated with higher likelihood of inpatient ASM prescription include intracranial injury on imaging (OR 57, 95% CI 24–156), moderate Glasgow Coma Scale score of 9 to 12 (OR 21, 95% CI 2.4–354), neurology/neurosurgery admission (OR 11, 95% CI 3.1–42), and immediate seizures (OR 3.6, 95% CI 0.77-23). Clinical factors associated with greater likelihood of discharge ASM prescription were neuroimaging abnormalities (OR 8.5, 95% CI 4.0–20), immediate seizures (OR 6.1, 95% CI 1.9–22), and neurology/neurosurgery admission (OR 2.1, 95% CI 0.71–6.8). Conclusions Neuroimaging abnormalities, seizures, and admission to neurology or neurosurgery services were associated with greater likelihood of ASM prescription during hospitalization and at discharge. Future studies are needed to determine whether ASM prescription improves outcomes and optimize ASM use.Keywords
All Related Versions
This publication has 34 references indexed in Scilit:
- A new characterisation of acute traumatic brain injury: the NIH-NINDS TBI Classification and Nomenclature InitiativeThe Lancet Neurology, 2025
- Effectiveness of Fosphenytoin and Levetiracetam to Prevent Posttraumatic Seizures in Young Children with Accidental or Abusive Traumatic Brain InjuryNeurocritical Care, 2024
- Early Seizure Prophylaxis in Mild and Moderate Traumatic Brain InjuryJAMA Neurology, 2024
- Guidelines for Seizure Prophylaxis in Adults Hospitalized with Moderate–Severe Traumatic Brain Injury: A Clinical Practice Guideline for Health Care Professionals from the Neurocritical Care SocietyNeurocritical Care, 2024
- Evaluation of levetiracetam for early post-traumatic seizure prophylaxis: A level II trauma center experienceThe Surgeon, 2022
- Risk Factors and Prognosis of Early Posttraumatic Seizures in Moderate to Severe Traumatic Brain InjuryJAMA Neurology, 2022
- Levetiracetam Prophylaxis for Children Admitted With Traumatic Brain InjuryPediatric Neurology, 2022
- Epileptiform activity in traumatic brain injury predicts post‐traumatic epilepsyAnnals of Neurology, 2018
- Validation of a Case Definition for Pediatric Brain Injury Using Administrative DataCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2017
- Seizures and the Role of Anticonvulsants After Traumatic Brain InjuryNeurosurgery Clinics of North America, 2016